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Rapport de synthèse 
L'infection par le virus de l'hépatite C (VHC) a une évolution sévère chez les 
patients co-infectés par VIHNHC, de même que chez les patients transplantés 
hépatiques. Toutefois, les mécanismes impliqués dans cette évolution restent 
peu clairs. 
Dans ce travail, nous étudions le profil fonctionnel des cellules T spécifiques 
dirigées contre le virus de l'hépatite C chez 86 patients mono-infectés par VHC, 
48 patients co-infectés par VIH/VHC et 42 patients ayant bénéficié d'une 
transplantation hépatique. La production d'IFN-Y et d'IL-2 et la capacité de 
proliférer des cellules T CD4+ et CD8+ sont évaluées après stimulation par des 
peptides dérivés du VHC. 
Chez les patients mono-infectés par le VHC, les cellules T spécifiques au VHC 
sont polyfonctionnelles du point de vue de la sécrétion de cytokines, avec trois 
profils de sécrétion pour les cellules T CD4+: sécrétion uniquement de IL-2, 
sécrétion de IL-2 et IFN-y et sécrétion uniquement de IFN- y, et de deux profils 
pour les cellules T CD8+: sécrétion de IL-2 et IFN-y et sécrétion uniquement de 
IFN- y. En revanche, les cellules T spécifiques au VHC chez les individus co-
infectés par VIHNHC et chez les patients transplantés hépatiques ont un profil 
de sécrétions de cytokines marqué par l'absence de cellules CD4+ sécrétant 
uniquement l'Il-2 et l'absence de cellules CD8+ sécrétant à la fois IL-2 et IFN-y. 
De plus, la prolifération de cellules T CD4+ et CD8+ spécifiques au VHC est 
considérablement réduite chez les patients co-infectés par VIHNHC, comme 
chez les transplantés hépatiques. 
La présence de cellules T effectrices uniquement (définies par l'absence de 
cellules T CD4+ sécrétants uniquement de l'IL-2 et l'absence de cellules T CD8+ 
sécrétant à la fois IL-2 et IFN-y et altération de la capacité proliférative) est 
associée avec une charge virale VHC significativement plus élevée et une 
fibrose hépatique plus sévère. Par conséquent, les présents résultats suggèrent la 
participation de mécanismes immunitaires dans l'évolution accélérée de 
l'hépatite C chez les patients co-infectés par VIH-1 et chez les patients greffés 
hépatiques. 
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HCV infection has a severe course of disease in HIV/HCV co-infection and in liver trans-
plant recipients. However, the mechanisms involved remain unclear. Here, we evaluated 
functional profiles of HCV-specific T-cell responses in S6 HCV mono-infected patients, 4S 
HIV/HCV co-infected patients and 42 liver transplant recipients. IFN-y and IL-2 production 
and ability of CD4 and CDS T cells to proliferate were assessed after stimulation with HCV-
derived peptides. We observed that HCV-specific T-cell responses were polyfunctional in 
HCV mono-infected patients, with presence of proliferating single IL-2-, dual IL-2/IFN-y 
and single IFN-y-producing CD4+ and dual IL-2/IFN-y and single IFN-y-producing CDS+ 
cells. In contrast, HCV-specific T-cell responses had an effector profile in HIV/HCV co-
infected individuals and liver transplant recipients with absence of single IL-2-producing 
HCV-specific CD4+ and dual IL-2/IFN-y-producing CDS+ T cells. In addition, HCV-specific 
proliferation of CD4+ and cos+ T cells was severely impaired in HIV/HCV co-infected 
patients and liver transplant recipients. Importantly, "only effector" T-cell responses were 
associated with significantly higher HCV viral load and more severe liver fibrosis scores. 
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Therefore, the present results suggest that immune-based mechanisms may contribute to 
explain the accelerated course of HCV infection in conditions of HIV-1 co-infection and 
liver transplantation. 
Key words: Cytokine production · Human · Proliferation · T-cell responses 
Introduction 
HCV infection is characterized by virus persistence in the majority 
of cases and by a long course of disease [1]. Indeed, HCV 
infection usually goes unrecognized for an undetermined period 
of time until liver disease becomes noticeable. Time from 
infection ta severe liver disease has been estimated to range 
between 20 and 30 years [l, 2], suggesting that a partial control 
of viral replication occurs in individuals with established chronic 
HCV infection. However, HCV-associated disease is highly 
accelerated and severe liver damage is evident as soon as 5-10 
years after infection in HIV-1/HCV co-infection [3, 4]. Similarly, 
liver transplant recipients in whom re-infection by HCV after 
transplantation invariably occurs, undergo a fast course of HCV-
associated disease, with a mean time ta cirrhosis similar ta that of 
HIV/HCV co-infected patients [5-7]. It has been observed that 
bath in conditions of HIV-1 co-infection and liver transplantation, 
HCV viral load was significantly higher (at least ten fold) than in 
HCV-infected non-transplanted individuals [S-10]. The immune 
suppression induced by HIV-1 infection most probably plays a 
role in the increased HCV viral load and faster progression of 
disease. In this regard, a negative correlation between CD4 
counts and HCV RNA levels [S, 9, 11] has been reported. In liver 
transplant recipients, increased HCV RNA levels are most 
probably due ta the immunosuppressive regimen [12]. Indeed, 
it has been shown that HCV RNA levels are related ta the levels 
of immunosuppression and ta the severity of liver histopathology 
[6]. Taken together these observations may indicate that 
HCV-specific immune responses are less effective in the 
control of virus replication in bath HIV-1/HCV co-infection 
and liver transplantation. It is, therefore, particularly important 
ta understand whether there are differences in HCV-specific 
T-cell responses in HCV mono-infected patients compared 
with HIV /HCV co-infected patients and li ver transplant 
recipients. 
Recent studies investigating the presence of HCV-specific 
T-cell responses in HIV-1 co-infected individuals have shown that 
their occurrence was not reduced [13-15] but the breadth of the 
response was limited and they were mostly composed of CDS+ 
T cells. Similarly, studies assessing the presence of HCV-specific 
T-cell responses in liver transplant recipients have shown that 
these were indeed detectable despite immunosuppression 
[16-20]. However, none of the studies in HIV/HCV co-infected 
patients and in liver transplant recipients have simultaneously 
investigated the presence of HCV-specific CD4+ and CDS+ T-cell 
responses throughout the complete HCV genome. More impor-
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tantly, there is limited information on the functional profile of 
HCV-specific T-cell responses in the setting of HIV/HCV co-
infection and liver transplantation. 
A series of studies have recently investigated the immune 
correlates of protective T-cell responses in various models of 
human virus infections [21]. These studies have shown that IFN-y 
and IL-2 production and proliferation capacity of CD4+ and 
CDS+ T cells are key functions ta define different levels of 
protection. In particular, it has been shown that immune 
responses associated with effective virus clearance or contra! 
(low ta undetectable viral load) were predominantly composed of 
polyfunctional CD4+ and CDS+ T cells. Polyfunctionality has 
been defined by the ability of bath CD4+ and CDS+ T cells ta 
produce cytokines such as IL-2 and IFN-y and ta proliferate 
[22-25]. Other cytokines such as MIP-1~ and TNF-a and func-
tions such as degranulation activity and perforin expression are 
instrumental ta better characterize the functional profile of T cells 
but do not discriminate between polyfunctional and "only effec-
tor" T-cell responses. Therefore, polyfunctional CD4+ T-cell 
responses are defined as being composed of single IL-2-produ-
cing, dual IL-2/IFN-y-producing and single IFN-y-producing 
T cells, and CDS+ T-cell responses are composed of dual IL-2/ 
IFN-y-producing and single IFN-y-producing T cells. Additionally, 
bath CD4+ and CDS+ T cells are able to proliferate. In contrast, 
"only effector" T-cell responses are characterized by the absence 
of single IL-2-producing CD4+ and of dual IL-2/IFN-y-producing 
CDS+ T cells and by the Jack of proliferation capacity. 
In the present study, we have identified and characterized 
bath HCV-specific CD4 + and CDS+ T-cell responses in blood 
mononuclear cells from HCV mono-infected patients, HIV/HCV 
co-infected patients and liver transplant recipients using over-
lapping peptides covering the whole HCV genome. We have then 
characterized these responses in terms of capacity of CD4 + and 
CDS+ T cells ta produce IFN-y and IL-2 and their ability 
ta proliferate. We have also analyzed the relationship between the 
functional T-cell profile and viral Joad as well as the severity 
of liver damage. 
Results 
Identification of HCV-specifi.c CD4 + and CD8+ T-cell 
responses 
In order ta characterize and compare the functional profile of 
HCV-specific T-cell responses in HCV mono-infected patients 
www.eji-journal.eu 
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versus HN/HCV co-infected patients and liver transplant recipients, 
individuals with detectable HCV-specific CD4+ or CDS+ T-cell 
responses were identified from a cohort of 176 chronically HCV-
infected patients composed of S6 HCV mono-infected patients, 4S 
HN/HCV co-infected patients and 42 liver transplant recipients. 
The patients studied had not been previously treated for HCV 
infection. HCV-specific T-cell responses were measured using pools 
of HCV-derived peptides encompassing the whole HCV genome in 
IFN-y ELISpot assays as previously described [14]. HCV-specific T-
cell responses were detected among 26 HCV mono-infected 
patients (30%), 16 HN/HCV co-infected patients (33%) and 14 
liver transplant recipients (33%) thus indicating that the overall 
frequency of HCV-specific T-cell responses was not different 
between the three study groups. In order to strengthen the present 
analyses, patients from our initial study that investigated HCV-
specific T-cell responses in HCV mono- versus HN /HCV co-infected 
patients [14] were also included. The patients from that previous 
study were HCV mono-infected patients M*-1, 2, 12, 23, 31, 36, 
46, 47, 49, SO, SS, S9, 60 and 63 (14 patients) and HN/HCV co-
infected patient C*-9 (Tables 1 and 2). Each HCV-specific T-cell 
response was confirmed using the individual HCV-derived corre-
sponding peptides in a second ELISpot assay (Tables 1 and 2). 
Characterization of the type ofT-cell populations (CD4 versus CDS) 
mediating HCV-specific responses was performed by measuring 
IFN-y production in ELlSpot assays with CD4- or CDS-depleted 
populations in patients for whom sufficient blood mononuclear 
cells were available (34 HCV mono-infected patients, 17 HN /HCV 
co-infected patients and 14 liver transplant recipients). The 
proportion of HCV-specific CD4+ and CDS+ T-cell responses was 
balanced in HCV mono-infected individuals. Indeed, 17 CD4+ and 
17 CDS+ HCV-specific T-cell responses were detected in 34 
patients tested. A tendency to a larger proportion of HCV-specific 
CDS+ T-cell responses was found in HN/HCV co-infected patients 
(10 out of 17), as previously observed [14, lS], while a larger 
proportion of co4+ T-cell responses was detected in liver 
transplant recipients (10 out of 14, Tables 1 and 2). 
Reduction in IL-2-producing HCV-specific T cells in 
patients with HIV-1 or liver transplantation 
It has been shown that polyfunctional T-cell responses were 
associated with more effective contrai of virus replication and 
lower viral Joad in chronic virus infections such as CMV, EBV, 
HCV, HIV-1 and HSV infections [22, 2S] whereas "only effector" 
T-cell responses were associated with higher viral Joad. As mono/ 
polyfunctionality of T-cell responses are predominantly defined 
by the ability of CD4 and CDS T cells to produce IL-2 and to 
proliferate, we analyzed these parameters in chronic HCV mono-
infection, HN /HCV co-infection and in liver transplant recipients. 
In order to analyze the profile of cytokine production by HCV-
specific T cells, blood mononuclear cells were stimulated with the 
cognate HCV-derived peptides and IFN-y and IL-2 production was 
assessed by intracellular cytokine staining. 
Substantial differences were observed in HCV-specific T-cell 
responses between the HCV mono-infected patients and the HN / 
© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
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HCV co-infected patients and liver transplant recipients. In HCV 
mono-infected patients, HCV-specific co4+ T-cell responses had 
a typical polyfunctional profile and were composed of single IL-2, 
dual IL-2/IFN-y and single IFN-y-producing cells (Fig. lA). On 
the contrary, single IL-2-producing HCV-specific CD4+ T cells 
were generally not detected in bath HN/HCV co-infected 
patients and liver transplant recipients in whom HCV-specific 
CD4 + T cells were predominantly dual IL-2/IFN-y and single IFN-
y-producing cells (Fig. lA). The analysis of cumulative data 
showed that the reduction in single IL-2-producing HCV-specific 
CD4+ T cells in HIV/HCV co-infected patients and transplant 
recipients was statistically significant (p=0.0002, Fig. 1B and 
Table 1). In addition, there was an increase in single IFN-y-
producing cells (p=0.04) in HN/HCV co-infected patients and 
liver transplant recipients as compared with patients with HCV 
mono-infection. The proportion of dual IL-2/IFN-y-producing 
cells was similar between the two groups (p=0.09). 
A comparable polyfunctional profile was observed in HCV-
specific cos+ T-cell responses in patients with HCV mono-
infection (Fig. lC) with the presence of dual IL-2/IFN-y and 
single IFN-y-producing cells. However, the proportion of dual 
IL-2/IFN-y-producing cells was significantly reduced in bath 
HN/HCV co-infected patients and liver transplant recipients in 
whom HCV-specific CDS+ T cells were composed almost exclu-
sively of IFN-y-producing cells (Fig. lC). The analysis of cumu-
lative data showed that the percentage of dual IL-2/IFN-y-
producing HCV-specific CDS+ T cells was significantly reduced in 
HN/HCV co-infected patients and liver transplant recipients 
as compared with HCV mono-infected individuals (p=0.001, 
Fig. 1D and Table 2). The differences shown in Fig. 1D for IL-2/ 
IFN-y-producing cells were not due to the single outlier HCV-
infected patient with a very high percentage of IL-2/IFN-y-
producing cells since they were still highly significant even 
excluding the outlier (p<0.001). No significant differences 
(p=0.14) were found in the proportion of single IFN-y-producing 
cells between HCV mono-infected patients and the HN/HCV co-
infected patients and liver transplant recipients group (Fig. lD). 
In order to rule out the possibility that the reduction in single 
IL-2-producing CD4+ and IL-2/IFN-y-producing CDS+ HCV-
specific T cells in HN/HCV co-infected patients and liver trans-
plant recipients was due to defective T-cell activation, we 
analyzed the up-regulation of the early activation marker CD69 
on HCV-specific CD4+ and CDS+ T cells after stimulation with the 
cognate HCV-derived peptide in five HCV mono-infected patients, 
five HN/HCV co-infected patients and five liver transplant reci-
pients. Ail cytokine-producing CD4+ or cos+ T cells co-expressed 
the CD69 marker in HCV mono-infected patients, HN/HCV co-
infected patients or li ver transplant recipients (not shown). 
Impaired proliferation of HCV-specific T cells in 
patients with HIV-1 or liver transplantation 
We next assessed the proliferation capacity of HCV-specific CD4 + 
and CDS+ T cells in HCV mono-infected patients, HN/HCV 
www.eji-journal.eu 
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Table 1. Profiles of IL-2, IL-2/IFN-y and IFN-y production and proliferation of HCV-specific co4+ T cells in HCV mono-infected 
patients, HIV/HCV co-infected patients and liver transplant recipients 
Patient code"l infection status HCV peptide amino acid sequence % cytokine-producing cellsbl src) 
IL-2 IL-2/IFN-y IFN-y 
CD4 T cell responses 
M*-2 HCV E2 688-702 GLIHLHQNIVDVQYL 0.01 0.03 0.03 9.8 
M*-12 HCV NS3 1511-1525 MFDSSVLCECYDAGC 0.12 0.08 0.06 na 
M*-23 HCV NS3 1511-1525 MFDSSVLCECYDAGC 0.01 0.03 0.03 na 
M*-31 HCV NS3 1583-1597 FPYLVAYQATVCARA 0.06 0.04 0.02 na 
M*-36 HCV NS4A 1658-1672 STWVLVGGVLAALAA 0.04 0.07 0.04 na 
M*-46 HCV c 133-147 LMGYIPLVGAPLGGA 0.03 0.02 0.02 6.2 
M*-63 HCV c 145-159 GGAARALAHGVRVLE 0.06 0.12 0.08 na 
M-78 HCV NS3 1511-1525 MFDSSVLCECYDAGC 0.01 0.02 0.04 4.4 
M-87 HCV c 133-147 LMGYIPLVGAPLGGA 0.18 0.12 0.06 3.8 
M-113 HCV E2 329-343 VVAIKVVEYVVLLFLLL 0.08 0.07 0.06 5.2 
M-119 HCV c 133-147 LMGYIPLVGAPLGGA 0.02 0.07 0.03 10.3 
M-120 HCV E2 720-736 VLLFLLLADARVCSC 0.05 0.02 0.01 na 
M-124 HCV NS3 1219-1233 VPQSFQVAHLHAPTG 0.09 0.10 0.05 7.1 
M-128 HCV NS4A 1658-1672 STWVLVGGVLAALAA 0.02 0.01 0.06 na 
M-151 HCV c 153-167 HGVRVLEDGVNYATG 0.23 0.11 0.11 7.5 
M-158 HCV NS3 1207-1221 SPVFTDNSSPPAVPQ 0.03 0.01 0.02 5.3 
M-178 HCV NS5A 2129-2143 RLHRFAPPCKPLLRE 0.11 0.05 0.02 5.3 
mean 0.07 0.06 0.04 6.5 
C-4 HIV/HCV NS3 1511-1525 MFDSSVLCECYDAGC 0 0.19 0.51 na 
C-10 HIV/HCV NS4A 1658-1672 STWVLVGGVLAALAA 0.01 0.05 0.17 1.2 
C-12 HIV/HCV NS3 1511-1525 MFDSSVLCECYDAGC 0 0 0.03 1.1 
C-47 HIV/HCV c 113-127 RRRSRNLGKVIDTLT 0.01 0.02 0.02 4.0 
C-48 HIV/HCV NS3 1511-1525 MFDSSVLCECYDAGC 0.01 0.21 0.15 2.6 
C-56 HIV/HCV NS3 1623-1637 PLLYRLGAVQNEVTL 0.05 0.57 0.28 3.1 
C-117 HIV/HCV c 33-47 GVYLLPRRGPRLGVR 0 0.02 0.02 1.5 
T-3 Liver transplant NS3 1511-1525 MFDSSVLCECYDAGC 0 0.25 0.29 1.0 
T-6 Liver transplant NS4A 1658-1672 STWVLVGGVLAALAA 0 0.02 0.05 1.1 
T-9 Liver transplant c 85-99 LYGNEGCGVVAGVVLLS 0.02 0.01 0.02 1.1 
T-23 Liver transplant E2 628-642 KVRMYVGGVEHRLEA 0 0.03 0.02 2.3 
T-24 Liver transplant NS4A 1658-1672 STWVLVGGVLAALAA 0 0.06 0.12 1.1 
T-25 Liver transplant NVV3 1511-1525 MFDSSVLCECYDAGC 0 0 0.19 1.3 
T-28 Liver transplant c 125-139 TLTCGFADLMGYIPL 0.01 0.01 0.02 0.8 
T-34 Liver transplant NS3 1511-1525 MFDSSVLCECYDAGC 0 0.64 1.6 0.8 
T-37 Liver transplant NS3 1511-1525 MFDSSVLCECYDAGC 0 0.02 0.03 1.3 
T-41 Liver transplant NS3 1511-1525 MFDSSVLCECYDAGC 0 0.02 0.05 na 
mean 0.01 0.12 0.21 1.6 
p 0.0002 0.09 0.04 <0.0001 
a) M: HCV mono-infected patient, C: HIV/HCV co-infected patient, T: liver transplant recipient. An asterisk denotes patients from 
our initial study [14]. 
b) Percentage of cytokine-producing cells among co4+ T cells. Results are shown with background in absence of peptide 
substracted. 
c) SI: stimulation index. SI were calculated by dividing the percentage of CFSE10w cells in presence of peptide by that in absence of 
peptide; na: not available due to high spontaneous proliferation in absence of peptide; nd: not done due to insufficient material. 
co-infected patients and liver transplant recipients after antigen-
specific stimulation in a 5-day CFSE assay. Recent studies have 
indeed shown that the proliferation capacity of virus-specific CD4 
and CDS T cells is dependent upon the presence ofIL-2-producing 
cells and that the presence of virus-specific proliferating cells is 
associated with contrai of virus replication [22, 24, 25]. Bo th 
© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
CD4+ (Fig. 2A) and cos+ (Fig. 2B) T cells were able to 
proliferate following stimulation with the HCV-derived cognate 
peptides in patients with HCV mono-infection. However, the 
ability to proliferate of both HCV-specific CD4 + and CDS+ T cells 
after stimulation with HCV-derived peptides was however 
severely impaired in subjects with HN/HCV co-infection or in 
www.eji-journal.eu 
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Table 2. Profiles of IL-2/IFN-y and IFN-y production and proliferation of HCV-specific CD8+ T cells in HCV mono-infected 
patients, HIV/HCV co-infected patients and liver transplant recipients 
Patient codea) infection status HCV peptide amino acid sequence % cytokine-producing cellsb) srcl 
IL-2/IFN-y IFN-y 
CDS T cell responses 
M*-1 HCV NS5B 2S93-2907 SLHSYSPGEINRVAA 0.06 0.02 12.2 
M-5 HCV pl 771-7S5 FFCFA\NYLKGRVVVPG 0.07 0.15 11.1 
M-S HCV NS5A 2121-2135 FFTELDGVRLHRFAP 0.03 0.27 4.2 
M-34 HCV E2 464-47S DFAQGWGPISYANGS 0.06 0.15 6.4 
M*-47 HCV E2 464-478 DFAQGWGPISYANGS 0.05 0.16 nd 
M-4S HCV NS5A 2121-2135 FFTELDGVRLHRFAP 0.03 0.18 na 
M*-49 HCV NS5B 2S93-2907 SLHSYSPGEINRVAA 0.06 0.03 7.5 
M*-50 HCV E2 464-47S DFAQGWGPISYANGS 0.02 0.06 7.2 
M*-55 HCV NS3 1355-1359 VTVSHPNIEEVALST 0.1 0.13 nd 
M*-59 HCV E2 692-706 LHQNIVDVQYLYGVG 0.06 0.04 na 
M*-60 HCV NS3 1227-1241 HLHAPTGSGKSTKVP 0.12 0.29 nd 
M-64 HCV E2 464-47S DFAQGWGPISYANGS 0.06 0.06 6.2 
M-67 HCV E2 712-726 WAIKWEYVVLLFLLL 0.01 0.06 9.2 
M-107 HCV E2 692-706 LHQNIVDVQYLYGVG 0.02 0.17 6.3 
M-10S HCV NS5B 2597-2611 DWSKLPLAVMGSSY 0.07 0.13 14.S 
M-121 HCV NS3 1227-1241 HLHAPTGSGKSTKVP 0.31 0.09 na 
M-129 HCV E2 536-550 VFVLNNTRPPLGNWF 0.01 O.OS 4.6 
me an 0.07 0.12 8.2 
C-5 HIV/HCV E2 6S4-69S ALSTGLIHLHQNIVD 0 0.12 1.1 
C-6 HIV/HCV NS3 1143-1157 RRRGDSRGSLLSPRP 0.01 0.06 na 
C-7 HIV/HCV NS4A 165S-1672 STVVVLVGGVLAALAA 0.01 0.09 na 
c*-9 HIV/HCV c 33-47 GVYLLPRRGPRLGVR 0.01 0.03 2.3 
C-11 HIV/HCV c 129-143 GFADLMGYIPLVGAP 0 0.14 1.1 
C-17 HIV/HCV E2 536-550 VFVLNNTRPPLGNWF 0.02 0.17 2.2 
C-1S HIV/HCV NS2 S50-S64 LTRVEAQLHVVVVPPL 0.01 0.11 1.5 
C-49 HIV/HCV NS3 1511-1525 MFDSSVLCECYDAGC 0.02 0.06 3.0 
C-S3 HIV/HCV E2 137-151 DRSGAPTYSWGANDT 0 0.05 1.4 
C-113 HIV/HCV NS4A 1662-1676 LVGGVLAALAAYCLS 0 0.11 2.9 
T-2 Liver transplant NS5B 2773-27S7 PPQPEYDLELITSCS 0 0.11 1.2 
T-30 Liver transplant NS4B 1712-1726 SQHLPYIEQGMMLAE 0 0.29 1.0 
T-31 Liver transplant NS5A 2137-2151 CKPLLREEVSFRVGL 0 0.3S 1.S 
T-32 Liver transplant not determined not determined 0 0.75 1.3 
me an 0.01 0.18 1.7 
p 0.001 0.14 <0.0001 
a) M: HCV mono-infected patient, C: HIV/HCV co-infected patient, T: liver transplant recipient. An asterisk denotes patients from 
our initial study [14]. 
b) Percentage of cytokine-producing cells among CDS+ T cells. Results are shown with background in absence of peptide 
substracted. 
c) SI: stimulation index. SI were calculated by dividing the percentage of CFSE10w cells in presence of peptide by that in absence of 
peptide; na: not available due to high spontaneous proliferation in absence of peptide; nd: not done due to insufficient 
material. 
liver transplant recipients (Fig. 2A and B). It is important to 
underscore that both CD4+ and CDS+ T cells were able to 
proliferate after stimulation with Staphylococcal enterotoxin B 
(SEB) in HIV/HCV co-infected individuals and liver transplant 
recipients (not shown). The analysis of cumulative data showed 
that the stimulation index (SI) was significantly reduced 
(p<D.0001) for CD4+ and CDS+ T cells in HIV/HCV co-infected 
patients or liver transplant recipients as compared with HCV 
© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
mono-infected patients (Fig. 2C and D). However, the impaired 
proliferation of HCV-specific T cells in HIV /HCV co-infected 
patients and liver transplant recipients was not the result of an 
intrinsic defect of T cells as the exogenous addition of IL-2 was 
able to restore HCV-induced proliferation in both CD4+ and 
CDS+ T cells. A representative example is shown in Fig. 2E for an 
HIV/HCV co-infected patient. This result also confirms that the 
lack of proliferation is linked to the lack of self IL-2 production. 
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Figure 1. Cytokine-production profiles of HCV-specific T cells in HCV mono-infected patients, HlV/HCV co-infected patients and liver transplant 
recipients. (A) Profiles of IFN-y and IL-2 production by HCV-specific CD4 + T ce lis in HCV mono-infected patients, HIV/HCV co-infected patients and 
liver transplant recipients after stimulation with the cognate HCV-derived peptide. Spontaneous cytokine production was assessed by incubating 
cells in absence of peptide. Numbers in quadrants represent the percentage of the corresponding cytokine-producing population among CD4' 
T cells. (B) Cumulative data analysis ofHCV-specific CD4+ T-cell responses in 17 HCV mono-infected patients, 7 HIV/HCV co-infected patients and 
9 liver transplant recipients. Open circles correspond to HIV/HCV co-infected patients and closed circles ta liver transplant recipients. (C) Profiles 
of IFN-y and IL-2 production by HCV-specific CDS' T cells in HCV mono-infected patients, HlV/HCV co-infected patients and liver transplant 
recipients after stimulation with the cogna te HCV peptide. (D) Cumulative data analysis of HCV-specific CDS+ T-cell responses in 17 HCV mono-
infected patients, 10 HIV/HCV co-infected patients and 4 liver transplant recipients. 
Changes in cytokine profiles and proliferation are 
restricted to HCV-specific T cells 
We next investigated whether the reduction in the single 
IL-2-producing CD4+ and dual IL-2/IFN-y-producing CDS+ 
antigen-specific populations as well as their lack of proliferation 
was a global T-cell dysfunction in HIV/HCV co-infected 
patients and liver transplant recipients. To this end, we analyzed 
the profiles of cytokine production and the proliferation 
capacity in CMV-, EBV- and HSV-specific T cells in these two 
groups of patients. Virus-specific CD4+ T-cell responses were 
assessed in HCV mono-infected patients (n = 19) and HIV/HCV 
co-infected patients or liver transplant recipients (n = lS) 
after stimulation with CMV, EBV or HSV lysates. As shown 
in Fig. 3A in a representative example, single IL-2-producing 
HSV-specific CD4 + T cells were clearly detectable in HCV 
mono-infected patients, HIV/HCV co-infected patients and liver 
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transplant recipients. Cumulative data of CMV-, EBV- and HSV-
specific CD4+ T-cell responses clearly demonstrated that 
the proportion of single IL-2-producing cells in response to 
contrai antigens was similar in the HCV mono-infected and 
HIV/HCV co-infected or liver transplant groups (p=0.35, Fig. 3B). 
These results indicated that the reduction in the single IL-2-
producing CD4+ T-cell population was restricted to HCV-specific 
cells in HIV/HCV co-infected individuals and liver transplant 
recipients. 
Similarly, we investigated whether there were differences in 
the frequencies of dual IL-2/IFN-y-producing CMV- and EBV-
specific CDS+ T cells in HCV mono-infected patients, HIV/HCV 
co-infected patients and liver transplant recipients. Cytokine 
production in response to pools of CMV- and EBV-derived 
peptides was analyzed in 13 HCV mono-infected patients 
and 25 HIV/HCV co-infected patients or liver transplant 
recipients. As shown in Fig. 3C for a representative example, dual 
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Figure 2. Proliferation of HCV-specific CD4 + and CDS+ T cells. (A) Proliferation of HCV-specific CD4 + T cells after stimulation with HCV-derived 
peptides in HCV mono-infected patients, HIV/HCV co-infected patients and liver transplant recipients. Spontaneous proliferation was assessed by 
incubating ce lis in absence of peptide. Numbers in quadrants represent the percentage of CFSE10w cells among CD4 + T cells. (B) Proliferation of 
HCV-specific CDS+ T cells after stimulation with HCV-derived peptides in HCV mono-infected patients, HIV/HCV co-infected patients and liver 
transplant recipients. (C) Cumulative data analysis of HCV-specific CD4+ T-cell proliferation in ten HCV mono-infected patients, six HIV/HCV 
co-infected patients and nine liver transplant recipients. SI was calculated by dividing the number of CFSE10w cells in the presence of peptide by 
that in the absence of peptide. Only SI> 3 were considered to be positive (dotted line). Open circles correspond to HIV/HCV co-infected patients and 
closed circles to liver transplant recipients. (D) Cumulative data analysis of HCV-specific CDS+ T-cell proliferation in 11 HCV mono-infected 
patients, 8 HIV/HCV co-infected patients and 4 liver transplant recipients. (E) Proliferation of HCV-specific CD4+ Tin the absence or in the presence 
of exogenously added IL-2 in a representative HIV/HCV co-infected patient. 
IL-2/IFN-y-producing CDS+ T cells were readily detected in HCV 
mono-infected patients, HIV/HCV co-infected patients and liver 
transplant recipients after stimulation with a pool of EBV-derived 
peptides. The analysis of cumulative data showed that there were 
no significant differences in the proportion of dual IL-2/IFN-y-
producing CMV- and EBV-specific CDS+ T cells between the two 
patient groups (p=D.29, Fig. 3D). Taken together these results 
indicated that the defect in the dual IL-2/IFN-y-producing CDS+ 
T-cell population was restricted to the HCV-specific CDS+ T-cell 
population in HIV/HCV co-infected patients and liver transplant 
recipients. 
With regard to proliferative capacity, we observed that, 
following antigen-specific stimulation, CMV-, EBV- or HSV-
© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
specific CD4+ T cells were able to proliferate in bath the HCV 
mono-infected patients (n = 15) and HIV/HCV co-infected 
patients and liver transplant recipients (n = 21). A representative 
example is shown in Fig. 3E for EBV-specific CD4+ T-cell 
responses. Similarly, CDS+ T cells stimulated with CMV- or EBV-
derived peptide pools were able to proliferate in HCV mono-
infected patknts (n = 13) and in HIV/HCV co-infected patients 
and liver transplant recipients (n = 24, Fig. 3F). Cumulative data 
confirmed that there were no significant differences in the 
proliferation capacity of bath CMV and EBV-specific CD4 + and 
CDS+ T cells in HCV mono-infected and HIV/HCV co-infected 
and liver transplant recipient groups (p=D.4S and 0.26, respec-
tively, Fig. 3G). 
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Figure 3. Cytokine production and proliferation of antigen-specific CD4' and CDS+ T cells in response to control antigens. (A) Profiles of IFN-y and 
IL-2 production by CD4+ T ce lis after stimulation with an HSV lysa te. (B) Cumulative data analysis of CD4' T cells in response to CMV, EBV or HSV 
lysates in 19 HCV mono-infected patients, 9 HIV/HCV co-infected patients (open circles) and 9 liver transplant recipients (closed circles). 
(C) Profiles of IFN-y and IL-2 production by CDS+ T cells after stimulation with a pool of EBV-derived peptides. (D) Cumulative data analysis of CDS+ 
T cells in response to pools of CMV- or EBV-derived peptides in 13 HCV mono-infected patients, 13 HIV/HCV co-infected patients and 12 liver 
transplant recipients. (E) Proliferation of CD4 + T cells after stimulation with an EBV lysa te. (F) Proliferation of CD8 1 T cells after stimulation with a 
pool of CMV-derived peptides in HCV mono-infected patients, HIV/HCV co-infected patients and liver transplant recipients. (G) Upper panel: 
cumulative data analysis of CD4 1 T-cell proliferation after stimulation with CMV-, EBV- or HSV lysates in 15 HCV mono-infected patients, 
11 HIV/HCV co-infected patients (open circles) and 10 liver transplant recipients (closed circles). Lower panel: cumulative data analysis of CD8+ 
T-cell proliferation after stimulation with pools of CMV- or EBV-derived peptides in 13 HCV mono-infected patients, 12 HIV/HCV co-infected 
patients and 12 liver transplant recipients. 
"Only effector" T cells are associated with higher HCV 
viral load 
Previous studies have shown presence of higher levels of HCV 
viral Joad in patients with HN/HCV co-infection [3, 26, 27] and 
© 2008 WILEY-VCH Verlag GmbH & Co. KGaA, Weinheim 
in patients with liver transplant [9-11]. In addition, it has also 
been shown that "only effector" and polyfunctional T-cell 
responses were generally associated with higher and lower levels 
of viral load in CMV and HN-1 infection, respectively [22, 25]. 
Therefore, we investigated whether higher levels of HCV viral 
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Figure 4. Differences in HCV viral Joad and liver fibrosis scores in HCV mono-infected patients and HIV/HCV co-infected patients and liver 
transplant recipients. (A) Distribution of HCV viral Joad in HCV mono-infected patients (n = 34) and HIV/HCV co-infected patients or liver 
transplant recipients (n = 24) is shown. Values are given in klU/mL. (B) Correlation between the proportion of single !L-2-producing co4+ T cells 
among total cytokine-producing HCV-specific CD4 + T cells and HCV viral Joad. The correlation coefficient is -0.46. (C) Proportion of patients with 
fibrosis (METAV!R score F4) in the HCV mono-infected and H!V/HCV co-infected and liver transplant recipient groups. 
load were present in HIV/HCV co-infected patients and liver 
transplant recipients compared with HCV mono-infected patients. 
To this end, we measured HCV viral load in patients with 
characterized functional profiles of HCV-specific T-cell responses. 
We indeed observed substantial differences in the plasma viral 
load in HCV mono-infected patients versus HIV/HCV co-infected 
patients and liver transplant recipients (Fig. 4A). The mean HCV 
viral load was 4S5±SSk!U/mL (mean±SEM) (range: 11-2.512) 
in the HCV mono-infected patients (n = 34) with polyfunctional 
T-cell responses and 7.015±2.695kIU/mL (range: 61-69.000) in 
the HIV/HCV co-infected patients and liver transplant recipients 
with "only effector" T-cell responses (n = 24, Fig. 4A). These 
differences were statistically significant (p=0.004) and indicated 
that substantial differences in the functional profile of HCV-
specific T cells were associated with different levels of control of 
virus replication in HCV mono-infected patients versus HIV/HCV 
co-infected patients and liver transplant recipients. Furthermore, 
a correlation was also found between the functional profile of 
HCV-specific CD4+ T-cell responses and viral load. Indeed, the 
proportion of single IL-2-producing CD4+ T cells within the total 
cytokine-producing HCV-specific CD4 + T-cell population was 
inversely correlated with viral load (Fig. 4B, r = -0.46, p=0.01), 
supporting a direct link between the functional T-cell profile and 
control of virus replication. 
"Only effector" T cells are associated with more severe 
liver fibrosis 
We further assessed the impact of polyfunctional versus "only 
effector" HCV-specific T-cell responses on the clinical status of 
patients. Liver biopsies were performed in all HCV mono-infected 
and HIV/HCV co-infected patients and in 21 out of 42 liver 
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transplant rec1p1ents. Among liver transplant rec1p1ents with 
HCV-specific T-cell responses, S out of 14 patients underwent 
liver biopsy. We did not observe differences in the levels of 
alanine aminotransferase and/or aspartate aminotransferase 
between the different groups of patients (Table 3). When 
analyzing levels of liver inflammation (A in METAVIR scores, 
Table 3), there were again no statistical differences between the 
HCV mono-infected patients and the HIV/HCV co-infected 
patients and liver transplant groups. There was, however, a 
statistically significant increase in the proportion of patients with 
cirrhosis (score F4) in the HIV/HCV co-infected and liver 
transplant recipient groups versus the HCV mono-infected group 
(Fig. 4C, p=0.04). Therefore, although the number of patients 
tested is quite small, these results further support the hypothesis 
that the "only effector" HCV-specific T-cell response is less 
efficient and thus is associated with more severe liver disease. 
Discussion 
In this study, we have characterized the function of HCV-specific 
T-cell responses under conditions of HCV mono-infection and in 
the setting in which HCV infection is associated with a variable 
degree of immunosuppression, namely caused by HIV-1 co-
infection or immunosuppressive therapy in liver transplantation. 
We demonstrate that there are major differences in the HCV-
specific T-cell responses between HCV mono-infected patients 
and HIV/HCV co-infected patients and liver transplant recipients. 
In HCV mono-infection, HCV-specific CD4+ and CDS+ T cells 
had a polyfunctional profile, with CD4 + T cells being composed 
of proliferating and single IL-2, dual IL-2/IFN-y and single IFN-y-
producing cells and CDS+ T cells composed of proliferating and 
dual IL-2/IFN-y and single IFN-y-producing cells. In HIV/HCV 
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Table 3. Clinical characteristics of HCV mono-infected patients, HIV/HCV co-infected patients and liver transplant recipients 
displaying HCV-specific T-cell responses 
HCV mono-infected HIV/HCV co-infected Liver transplant 
patients patientsa) recipients 
HCV genotype 1a 7b) 5 2 
1b 5 5 7 
2 3 2 0 
3 12 3 3 
4 4 1 0 
uk 3 1 2 
C04 counts (cells/mL)c) 1150±84 674±66 na 
ALT (U/L)c) 90±9 75±8 60±9 
AST (U/L)c) 55±5 62±6 48±14 
Liver inflammation AO-A1 2obl 7 2 
A2-A3 11 8 2 
Liver fibrosis FO-F1 17 7 3 
F2-F3 11 4 4 
F4 3 4 1 
a) All HIV/HCV co-infected patients with HCV-specific T-cell responses had undetectable HIV viral load except for patient C-113 
(viramia: 22 000 copies/µL of serum). 
b) Expressed as number of patients. 
c) Mean±SEM. ALT: alanine aminotransferase, AST: aspartate aminotransferase, na: not available, uk: unknown. 
co-infected patients and liver transplant recipients, HCV-specific 
T cells had the "only effector" functional profile with a strong 
reduction in proliferating and IL-2-producing C04+ and COS+ 
T cells. These results show that HCV-specific T cells in HCV mono-
infection have a polyfunctional profile similar to that of virus-
specific CD4+ and cos+ T cells found in normally controlled 
infections with low or undetectable persistent viral Joad such as 
CMV, EBV, HSV, influenza and HIV-1-infected subjects with non-
progressive disease [22, 25, 2S]. In contrast, HCV-specific T-cell 
responses in HIV/HCV co-infected individuals and liver trans-
plant recipients have the "only effector" profile and resemble 
those detected in uncontrolled viral infections such as untreated 
viremic HIV-1 infection [22, 25]. The reduction in IL-2-producing 
co4+ and COS+ T cells can directly explain the impaired capacity 
of these cells to proliferate [25]. Therefore, although there were 
not significant quantitative differences in the frequencies and in 
the magnitude of HCV-specific T-cell responses in the three 
groups of patients studied, there were substantial qualitative 
differences in the functional profile of HCV-specific T-cell 
responses between HCV mono-infected patients and HIV /HCV co-
infected patients or liver transplant recipients. 
The "only effector" HCV-specific T-cell responses in HIV/HCV 
co-infected patients and liver transplant recipients were asso-
ciated with significantly higher levels of HCV viral load as 
compared with HCV mono-infected individuals with polyfunc-
tional responses. Therefore, qualitative, and not quantitative, 
differences of HCV-specific T-cell responses seem to influence the 
effectiveness of HCV-specific T-cell responses in mediating their 
antiviral effect and controlling viral replication. 
"Only effector" HCV-specific T-cell responses were also asso-
ciated with a more severe liver disease as the proportion of 
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patients with cirrhosis was higher in the HIV/HCV cc-infection 
and liver transplant group than in the HCV mono-infection group. 
The HCV genotype has been shown to influence the course of 
HCV disease and the response to antiviral treatment. It is 
important to note that there was no significant increase in the 
proportion of genotypes 1 and 4 in patients with cirrhosis both in 
HCV mono-infected individuals and in HIV/HCV co-infected 
individuals and liver transplant recipients. There was also no 
significant difference in the proportion of favorable genotypes 
(2 and 3) between HCV mono-infected patients and HIV/HCV co-
infected patients or liver transplant recipients (4S versus. 31 and 
25%, respectively, P> 0.05 for both comparisons). Therefore, the 
association between polyfunctional HCV-specific T-cell responses 
and HCV mono-infection cannot be explained on the basis of a 
more favorable virus genotype. Considering liver transplant reci-
pients, there were no significant differences in either profiles of 
IFN-y and IL-2 production, proliferation index, viral load or 
histopathological findings when analyzing patients according 
to immunosuppressive treatment with calcineurin inhibitors 
(cyclosporin or tacrolimus) versus rapamycin. However, one 
limitation of the histopathological correlation analysis in 
liver transplant recipients is that not all patients underwent liver 
biopsies. 
The absence of polyfunctional HCV-specific T-cell responses in 
HIV/HCV cc-infection and in liver transplantation may be 
dependent upon a number of factors. These include a lower CD4 + 
T-cell counts in co-infected patients [14, 15] and the immuno-
suppressive therapy in liver transplantation. In this regard, it is 
worth mentioning that C04 T-cell counts were significantly lower 
in HIV/HCV co-infected patients as compared with HCV 
mono-infected patients (Table 3, P<0.001). However, other 
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virus-specific (CMV, EBV and HSV) T-cell responses were not 
affected in HIV/HCV co-infection and liver transplant recipients. 
Furthermore, the defect was selective for IL-2-producing and 
pro!iferating HCV-specific T cells since the frequencies of IFN-y-
producing HCV-specific T cells were comparable in HCV mono-
infection, HIV/HCV co-infection and liver transplantation. 
The major difference between HCV and contra! viruses is that 
HCV continually replicates and it is clearly detectable in the blood 
whereas CMV, EBV and HSV do not replicate actively and reac-
tivate transiently. CMV and EBV replication can be detected in the 
blood only in the presence of severe immunosuppression. 
Therefore, it is not excluded that differences for the other virus-
specific T-cell responses can be detected when re-activation of 
virus replication occurs in the presence of severe immunosup-
pression. 
We have previously shown that the levels of viral load influ-
ence the functional profile of T-cell responses in HIV-1 and CMV 
infections under conditions of uncontrolled virus replication. In 
particular, high levels of viral Joad are associated with "only 
effector" T-cell responses. One attractive explanation for the 
presence of "only effector" HCV-specific T-cell responses in HIV/ 
HCV co-infected patients and liver transplant recipients, there-
fore, is that the presence of immunosuppression in these patients 
may favor more active virus replication. The higher levels of virus 
Joad may in turn impair polyfunctional responses while main-
taining the generation of "only effector" T-cell responses. 
Therefore, the presence of the "only effector" HCV-specific T-cell 
responses is consistent with the higher levels of HCV viral load 
found in HIV/HCV co-infected patients and liver transplant 
recipients. In this regard, it would be interesting to investigate 
whether polyfunctional HCV-specific T cells may be restored after 
suppression of HCV viral load following antiviral treatment. 
Indeed, suppression of HIV viral load following antiretroviral 
treatment in HIV-1-infected individuals was associated with the 
restoration of polyfunctional HIV-specific CD4 + and CDS+ T-cell 
responses in a significant proportion of individuals [21, 29]. 
It is worth mentioning that polyfunctional responses are 
generated during HCV mono-infection in the presence of levels of 
viral Joad much greater than those found in CMV and EBV 
infections or non-progressive HIV-1 infection. Therefore, these 
results indicate that only under conditions of immunosuppression 
associated with HIV/HCV co-infection and liver transplantation, 
the further increase in viral Joad levels drives the generation of 
"only effector" HCV-specific T-cell responses. These, in turn, are 
associated with poor contra! of virus replication. The long and 
relatively benign course of HCV mono-infection before the 
eventual progression to liver cirrhosis suggests that an efficient 
although not optimal contra! is mediated by the observed poly-
functional T-cell responses. 
In conclusion, polyfunctional T-cell responses are associated 
with a more effective contrai of virus replication during HCV 
mono-infection. The present results support the concept that 
immune-based mechanisms are involved in the modulation of the 
course of HCV infection in humans. Finally, whether functional 
profiles of T-cell responses may become valuable surrogate 
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markers of HCV disease activity remains to be studied in 
prospective studies. 
Material and methods 
Patients and samples 
Eighty-six chronically HCV mono-infected, 48 HIV/HCV co-infected 
patients and 42 HCV-infected patients having undergone liver 
transplantation for end-stage liver disease due to HCV-related 
cirrhosis were enrolled in this study that conformed to the ethical 
guidelines of the 1975 Declaration of Helsinki and was approved by 
the Institutional Review Board of al! centers concerned. Al! patients 
gave written informed consent. Ail HCV mono-infected patients, 
HIV/HCV co-infected patients and liver transplant recipients were 
naïve to antiviral treatment for HCV infection. Thirty-six out of the 
48 HIV/HCV co-infected individuals were on antiretroviral treat-
ment for HIV-1 infection. Ail liver transplant recipients were 
clinically stable (no evidence of rejection) and received a first 
cadaveric graft. Ali were studied more than 12 months after 
transplantation. Immunosuppressive therapy for liver transplant 
recipients consisted of cyclosporin monotherapy (n = 8), tacrolimus 
monotherapy (n = 7), cyclosporin or tacrolimus in combination 
with mycophenolate mofetil (n = 15), or in combination with 
prednisone (n = 3), or in combination with azathioprine (n = 5), 
rapamycin monotherapy (n = 2) and rapamycin in combination 
with azathioprine (n = 2). Peripheral blood (twice 50 mL) was 
obtained from ail patients by venipuncture and lymphocytes were 
isolated from peripheral blood samples upon centrifugation on a 
Ficoll gradient (Amersham Biosciences, Otelfingen, Switzerland) 
and either directly used for ELISpot assays or cryopreserved for 
further analyses. Liver biopsies were performed in ail HCV mono-
infected and HIV /HCV co-infected patients at time of HCV infection 
diagnosis. Biopsies were performed in 21 out of 42 liver transplant 
recipients at rime of elevation of liver enzymes. Ail biopsies were 
evaluated for extent of inflammation and fibrosis and scored using 
the METAVIR system [30]. 
Synthetic peptides and peptide pools 
A total of 728 peptides (15 aa long overlapping by 11 aa) 
corresponding to the HCV la strain and spanning ail HCV 
proteins were reconstituted in sterile DMSO and diluted to 
prepare peptide pools or used as individual peptides. The 728 
HCV-derived peptides were used to generate 54 peptide pools in a 
matrix settin~ [14]. Each pool was composed of 27 peptides and 
each peptide was present in two different pools, allowing for 
identification of the respective peptide by response in the two 
corresponding pools. Each peptide was present in the pools at the 
same concentration. Ali individual peptides or peptide pools were 
aliquoted and stored at-S0°C. CMV, EBV and HSV lysates were 
obtained from Applied Biosystems (Rotkreutz, Switzerland). 
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Pools of CMV- or EBV-derived peptides consisting of the 
corresponding peptides from the CEF control peptide pool [31] 
were obtained from Synpep Corporation (Dublin, CA, USA). Ail 
were reconstituted, aliquoted and stored at -80°C. 
IFN-y ELISpot assay 
IFN-y ELISpot assay was performed as previously described [14]. 
Briefly, 200 000 blood mononuclear cells were incubated in 
triplicate in the presence of peptide pools or individual peptides 
(5 ~tg/mL) for 18 h at 37°C. For ELISpot assays with depleted 
populations, CD4+ or CDS+ T cells were positively selected using 
magnetic beads (Miltenyi Biotech, Bergisch Gladbach, Germany) 
and incubated as described above. Spontaneous IFN-y production 
was assessed by incubation of cells in the absence of peptide and 
incubation of cells with SEB (0.2 µg/mL) (Calbiochem, La Jolla, 
CA, USA) was used as positive control. Responses were expressed 
as number of spots per 106 blood mononuclear cells. Twenty 
uninfected healthy donors were used in order to validate the use of 
the ELISpot assay. The significance of the ELISpot was determined 
as follows: using peripheral blood mononuclear cells from patients, 
the assay was considered experimentally valid only if the number 
of spots in the absence of peptide was below 50 spots per 106 blood 
mononuclear cells and the number of spots in response to the 
peptides was greater than 55 spots per 106 blood mononuclear 
cells and at least fourfold above the background level. This eut-off 
was obtained by calculating the mean plus 3 standard deviations of 
the mean responses observed with blood mononuclear cells of the 
20 healthy controls. Pools of HCV-derived peptides were used in 
the initial screening for presence of HCV-specific T-cell responses 
in HCV mono-infected patients, HN/HCV co-infected patients and 
liver transplant recipient. Individual HCV-derived peptides were 
then identified and confirmed in a second ELISpot assay. 
Individual HCV-derived peptides were then used for intracellular 
cytokine production or proliferation experiments. 
Multiparameter flow cytometry and antibodies 
Ail antibodies used were from BD Biosciences (Franklin, NJ, USA) 
unless stated otherwise. For intracellular IFN-y and IL-2 detec-
tion, cryopreserved peripheral blood mononuclear cells were 
incubated for 12 h in the presence or absence of the correspond-
ing HCV-derived individual peptides, pools of CMV- or EBV-
derived peptides, CMV, EBV or HSV lysates together with anti-
CD28 (1 µg/mL) and Brefeldin A (GolgiPlug, 1 µL/mL, BD 
Biosciences). Cells were then stained for extracellular markers, 
permeabilized (Perm-2, BD Biosciences) and stained for 
intracellular markers. Antibodies used were: IFN-lITc, IL-2PE, 
CD4PercP-cys.s and CDSAPc. Data were acquired on a FACSCalibur 
and analyzed using Cel!Quest™ software (BD Biosciences). 
Twenty uninfected healthy donors were used in order to validate 
the use of the intracellular cytokine staining assay with the sets of 
HCV-derived peptides. For intracellular cytokine staining assays 
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to be valid, the background in the unstimulated control 
(incubation in absence of peptide) had not to exceed 0.01 % 
and the percentage of cytokine-secreting cells had to have a 
background of less than 20% of the total percentage of cytokine-
positive cells in the stimulated samples and be at least threefold 
above level in unstimulated samples. This cut-offwas obtained by 
calculating the mean plus 3 standard deviations of the responses 
observed with blood mononuclear cells of 20 healthy controls 
testing the individual HCV peptides. 
Ex vivo proliferation assay 
Proliferation assays were performed as previously described [25]. 
Peptide concentration used for stimulation was 20 ng/mL. SEB 
(20 ng/mL) was used as positive control. No exogenous IL-2 was 
added except where specifically stated (rhIL-2, 10 IU/mL, Roche, 
Mannheim, Germany). Cells were harvested at day 5 and stained 
with CD3PercP-cys.s and CD4 or CDSAPC (BD Biosciences). Data 
were acquired on a FACSCalibur and analyzed using CellQuest™ 
software (BD Biosciences). SI was calculated as the ratio of the 
number of CFSE1°w cells in the presence relative to that in the 
absence of peptide. An SI> 3 was considered to be significant. 
Statistical analysis 
Comparison of two means was calculated by two-sample t-test. A 
p value <0.05 was considered to be significant. 
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